CytRx (CYTR) and Cephalon (CEPH) Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia
More News related to CEPH
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
- Cephalon, Inc. to Webcast R&D Day
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
- Trading Review for Jazz Pharmaceuticals Inc. Issued by Beacon Equity
- Soleil Securities Reiterates a 'Buy' on Cephalon (CEPH)
More News related to CYTR
- CytRx to Initiate Phase 2 Clinical Trial with INNO-206 in Patients with Advanced Gastric Cancer
- CytRx Corporation (CYTR) Tops Q3 EPS by 3c
- CytRx Reports 2009 Third Quarter Financial Results
- CytRx Announces Publication of Paper Stating that Chaperone Amplification Represents a 'Significant Strategy' in Anti-aging Pharmaceutical Design
- CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
CytRx Corporation (NASDAQ: CYTR) announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX (arsenic trioxide) injection marketed by Cephalon (Nasdaq: CEPH) in patients with relapsed acute promyelocytic leukemia (APL). There are two primary trial objectives. The first is to determine the safety and preliminary efficacy of combining tamibarotene with arsenic trioxide as a treatment for relapsed or refractory APL.
The second objective is to determine the appropriate dose for future clinical trials in which CytRx would test the utility of the tamibarotene/arsenic trioxide combination as a first-line treatment for subjects who prefer not to be exposed to anthracyclines. The dose escalation study is being financed jointly by CytRx and Cephalon.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.10
+0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
